Renal Cell Cancer, An Issue of Hematology/Oncology Clinics of North America
- 1st Edition, Volume 37-5 - September 15, 2023
- Latest edition
- Editors: Bradley A. Mcgregor, Toni K. Choueiri
- Language: English
In this issue of Hematology/Oncology Clinics, guest editors Drs. Bradley A. McGregor and Toni K. Choueiri bring their considerable expertise to the topic of Renal Cell Cancer. Top… Read more
Purchase options
In this issue of Hematology/Oncology Clinics, guest editors Drs. Bradley A. McGregor and Toni K. Choueiri bring their considerable expertise to the topic of Renal Cell Cancer. Top experts in the field cover key topics such as VHL and HIF at the center of renal cell cancer biology; immunobiology and metabolic pathways of renal cell cancer; hereditary renal cell cancer syndromes; the role of the pathologist in renal cell cancer; novel imaging in renal cell cancer; and more.
-
Contains 18 relevant, practice-oriented topics including the role of surgery in metastatic renal cell cancer; emerging biomarkers in metastatic renal cell cancer; choosing the right treatment for renal cell cancer of variant histology; novel targets in the treatment of renal cell cancer; and more.
-
Provides in-depth clinical reviews on renal cell cancer, offering actionable insights for clinical practice.
-
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
renal cell carcinoma, kidney cancer, hypernephroma
von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology
Immunobiology and Metabolic Pathways of Renal Cell Carcinoma
Hereditary Renal Cell Carcinoma Syndromes
The Role of the Pathologist in Renal Cell Carcinoma Management
Insights into Renal Cell Carcinoma with Novel Imaging Approaches
Surgical Management of Localized Disease and Small Renal Masses
Role of Surgery in Metastatic Renal Cell Carcinoma
Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma
Role of Radiation in Treatment of Renal Cell Carcinoma
Prognostic Models in Metastatic Renal Cell Carcinoma
Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma
Managing First-Line Metastatic Renal Cell Carcinoma: Favorable-Risk Disease
First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Managing Metastatic Renal Cell Carcinoma after Progression on Immunotherapy
Renal Cell Carcinoma of Variant Histology: Biology and Therapies
Toxicity Management of Systemic Kidney Cancer Therapies
Management of Brain Metastases in Metastatic Renal Cell Carcinoma
Novel Targeted Therapies for Renal Cell Carcinoma: Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition
Novel Immune Therapies for Renal Cell Carcinoma: Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes
Immunobiology and Metabolic Pathways of Renal Cell Carcinoma
Hereditary Renal Cell Carcinoma Syndromes
The Role of the Pathologist in Renal Cell Carcinoma Management
Insights into Renal Cell Carcinoma with Novel Imaging Approaches
Surgical Management of Localized Disease and Small Renal Masses
Role of Surgery in Metastatic Renal Cell Carcinoma
Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma
Role of Radiation in Treatment of Renal Cell Carcinoma
Prognostic Models in Metastatic Renal Cell Carcinoma
Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma
Managing First-Line Metastatic Renal Cell Carcinoma: Favorable-Risk Disease
First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Managing Metastatic Renal Cell Carcinoma after Progression on Immunotherapy
Renal Cell Carcinoma of Variant Histology: Biology and Therapies
Toxicity Management of Systemic Kidney Cancer Therapies
Management of Brain Metastases in Metastatic Renal Cell Carcinoma
Novel Targeted Therapies for Renal Cell Carcinoma: Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition
Novel Immune Therapies for Renal Cell Carcinoma: Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes
- Edition: 1
- Latest edition
- Volume: 37-5
- Published: September 15, 2023
- Language: English
BM
Bradley A. Mcgregor
Affiliations and expertise
Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer InstituteTC
Toni K. Choueiri
Affiliations and expertise
Jerome and Nancy Kohlberg Professor, Medicine, Harvard Medical School, Attending Physician, Solid Tumor Oncology, Dana-Farber Cancer Institute, Director, Genitourinary (GU) Oncology Disease Center,Dana-Farber Cancer Institute